Abstract. A recombinant DNA Plasmodium vivax sporozoite vaccine containing the repeating region of the Salvador I strain circumsporozoite (CS) protein was produced in Escherichia coli. This vaccine was tested in 13 naive volunteers at doses of 10-1,000 pg. No serious adverse reactions were noted. None of 4 volunteers receiving the 10 pg dose developed antibodies measurable by ELISA. Six of 9 volunteers in the other dose groups developed measurable antibodies: 5 of 5 volunteers receiving 100 pg and 1 of 4 receiving 1,000 pg. Antibody responses measured by immunofluorescence assays paralleled those seen by ELISA. None of the volunteers developed antisera that inhibited sporozoite invasion of human hepatoma cells in vitro. Lack of a classical anamnestic response and lack of a typical dose response to increasing amounts of antigen suggests the possible presence of an immunosuppressive epitope in the repetitive region of the CS protein.
The immunodominant protein covering the GQPA). A fragment of the gene encoding the 20 surface of malaria sporozoites, the circumspo-tandem repeats (V20) has been cloned into Eschrozoite (CS) protein, continues to be a major erichia coi * 0 and expressed as a fusion protein target in the development of an effective anti-with NS 1 s (81 amino acids from the N-terminus sporozoite malaria vaccine. Animals and hu-of the nonstructural protein NS I of influenza A mans immuniztd with irradiated sporozoites de-virus). NS Is, was chosen as part of the fusion velop antibodies directed against the respective protein with the P. vivax repeat region because CS protein and are protected against infection it may provide T cell epitopes important in the when challenged with sporozoites administered induction of cell mediated immunity.' 0 The NS either iv or by mosquito bite.'-3 Passive transfer Is, V20 fusion protein, which is expressed at high of monoclonal antibodies (Mabs) directed against levels and readily purified, has been shown to the immunodominant repeat region of the Plas-induce significant antibody responses in New modium berghei CS protein can confer protec-Zealand White rabbits (G. Wasserman, personal tion, in a dose dependent fashion, to recipient communication) and Saimiri sciureus bolivenanimals subsequently challenged with viable sis." sporozoites. 4. 3 These data have provided the imStudies in our laboratory with a related fusion petus to develop and test subunit vaccines de-protein, R32NS 18, (composed of 32 tetrapeptide signed to elicit antibodies to the repeating NANP/ repeats from the P. falciparum repeat region ex-NVDP epitope found in the P. falciparum CS pressed as a fusion protein containing the same protein. 6.7 The gene which codes for the CS pro-81 amino acids from NS 1), showed that BALB/ tein of P. vivax has also been cloned and se-c mice, which are nonresponders to R32 when quenced, and the amino acid sequence of the expressed as R32NSla,, are capable of develsporozoite surface protein deduced. 8 , 9 The CS oping high titers of antibodies to the P. falcipaprotein of P. vivax is analogous to other CS pro-rum repeat epitopes after they have been exposed teins and contains a highly charged region near to and have seroconverted to the A/PR/8/3 strain the amino terminus followed by an area of re-of influenza A. This suggests that prior infection peating amino acids. In P. vivax, the immuno-with influenza A may enhance the antibody redominant region consists of 20 tandem repeats sponse to the malaria repeat epitopes presented of the 9 amino acid sequence Gly-Asp-Arg-Alawith NSI,,. All tests were performed within 2 weeks before immunization. Subjects were excluded from participation if they had been in a malarious area C. 1000 n dam within 1 year of the start of the study, if they had 10.. previously had vivax malaria as determined by
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history, if the malarial antibody tests were pos-5
itive, if they had had a splenectomy, or if they
had had any cardiovascular, hepatic, renal, or immunological illness, or were taking any im-0 t / munosuppressive medications. Thirteen volun-0 2 9 17 teers, 7 males and 6 females, meeting the above Wwk criteria gave informed consent and entered this Ftonua . Antibody response to PVSV-l as mea-study. sured by ELISA. Results are reported in OD units, i.e., that serum dilution that would result in an absorbance Vaccine preparation of I at 414 nm in our standard ELISA. Doses of vaccine were administered at 0, 7, and 15 weeks. NS1 8 1 V20 is a 26,692 dalton, single chain polypeptide of 265 amino acids with the followR32NSIs, was safe, well tolerated, and able to ing sequence: induce partial protection against sporozoite chal-MDPNTVSSFQ VDCFLWVRKR lenge as manifested by a delay in the pre-patency VADQELGDAPF period in individuals exposed to P. falciparum LDRLRRDQKS LRGRGSTLGL using a laboratory developed challenge model (J. DIETATRAGKQ E. Egan, WRAIR, personal communication).
IVERILKEES DEALKMTMQI P Based on the above information, we consid-(GDRADGQPA) 4 (GDRAAGQPA), ered NSI@IV20 to be a good candidate for a hu-(GDRADGQPA) 4 (GDRAAGQPA) 2 man P. vivax sporozoite vaccine. We now report (GDRADGQPA), (GDRAAGQPA), the results of a study in human volunteers to (GDRADGQPA), (GDRAAGQPA), evaluate the safety and immunogenicity ofalum-(GDRADGQPA), (GDRAAGQPA),. adsorbed NS 1, V20, referred to as P. vivax spo-NS 1 8 ,V20 was produced by inserting a BstNlrozoite vaccine I (PVSV-I).
MnIl restriction enzyme fragment encoding the repeat domain of the P. vivax, Salvador I (Sal-MATERA.3 AND WMODS 1) strain, CS protein coding sequence into a vector which expresses 81 amino acids of the NS I Study subjects non-structural protein of A/PR/8/34 (H I N 1) influenza virus, creating the plasmid pNSIgIV20. Volunteers were recruited under a protocol ap-An E. coli expression strain, a derivative of the proved by The Army Surgeon General's Human standard NIH E. coli K12 strain N99 Subjects Research Review Board. Healthy men (F-su-galK2lacZ-thr-), was then transformed with pNS I, V20 and used to produce the initial Serological assays cell paste. Subsequently, crude NSIsV20 was obtained, following the mechanical disruption of CS antibodies were measured using a standard the cells, by a series of precipitation steps with ELISA technique 2. 3 except that a recombinant polyethyleneimine, ammonium sulfate, and protein, referred to as VIVAX-1, which con-* acidic pH conditions. Further purification of tained the entire repeat region of P. vivax flanked NSIsV20 consisted of ion exchange chroma-by the 15 amino acids amino terminal and the t tography on sulfopropyl-sepharose, size exclu-48 amino acids carboxy-terminal of the repeats, sion chromatography on superose 12, and re-was used as the capture antigen.' 4 This molecule versed-phase high performance liquid does not contain the NSI, segment present in chromatography on Vydac C-4 packing. Ho-PVSV-I. Horseradish-peroxidase conjugated mogeneity of the final product was confirmed by rabbit anti-human IgG (gamma chain specific) immunoblot analysis with antisera directed was used as the secondary antibody. Assays were against NS 1 and a Mab specific for the P. vivax run in triplicate and the mean absorbance and repeat region, analytical size exclusion, and RP-standard deviation was calculated for each di-HPLC.
lution. NSIsV20 was supplied by SmithKline BeeImmunofluorescence assays were performed cham Pharmaceuticals, Swedeland, PA, as a 4-as previously described.'
2 Hand dissected salivial multi-pack designated P. vivax sporozoite vary-gland sporozoites from the Sal-I strain of vaccine 1 (PVSV-1). Vial no. I contained 0.4 ml P. vivax were suspended in Medium 199, conof the NS 1 sV20 antigen solution at 7 mg/ml in taining 0.0 1% (v/v) bovine serum albumin, dota 50 mM acetate buffer, pH 5.5. Vials nos. 2A ted onto multi-well immunofluorescence assay and 2B contained the diluent (50 mM acetate slides at 10,000 sporozoites/dot, air-dried at room buffer, pH 5.5) supplied in 2 sizes, 1.8 ml/vial temperature, and stored at -70*C until used. (no. 2A) and 19.8 ml/vial (no. 2B). Vial no. 3 Antibodies reactive to sporozoites were detected contained the adjuvant suspension consisting of with fluorescein-labeled anti-human IgG under 0.5 ml of 4.4 mg/mI aluminum oxide (2.2 mg/ ultraviolet light at 500 x magnification. Fluoresml Al++) in 50 mM acetate buffer, pH 5.5, with cence was graded from 0 to +4, where 0 indicates 0.005% w/v thimerosal as a bactericide. The sys-no fluorescence detectable and +4 indicates intem is such that a 0.5 ml dose containing either tense fluorescence over the entire surface of the 10, 100, or 1,000 #g of NSl IV20 and 2.2 mg of sporozoite. aluminum oxide could easily be made just prior Percent inhibition of sporozoite invasion of to administration. All components of PVSV-I HepG2A-16 human hepatoma cells in vitro was were stored at 4"C prior to use. calculated according to Hollingdale.' s
Immunization schedule

RESULTS
Volunteers were randomly assigned to I of 3 The 13 individuals (mean age 35 years, range groups and received either 10, 100, or 1,000 pg 22-44 years), were randomly divided into 3 ofNSltV20as PVSV-1 im at week 0, with iden-groups to receive PVSV-1. The vaccine was welltical booster doses being given at 7 and 15 weeks. tolerated by all. The major side effect noted was Volunteers were observed for 20 min after each minor discomfort at the injection site in all voldose for immediate reactions and evaluated at unteers, which resolved within 24 hr. Two in-24 and 48 hr for symptoms of headache, fever, dividuals in the 1,000 ug dose group noted the chills, malaise, local pain, fever, erythema, onset of malaise and generalized myalgias 6-9 warmth, induration, lymphadenopathy, and oth-hr after the administration of the second dose of er complaints. Prior to and again 2 days after vaccine. These symptoms resolved after 48 hr. each dose of vaccine, each volunteer had blood One of these individuals continued in the study, and urine collected for evaluation. Serum sam-receiving the third dose of vaccine as scheduled, pies were obtained each week for 3 weeks after and experienced no untoward reaction, suggesteach dose. Whole blood was allowed to clot at in& that the previous reaction was not causally room temperature, serum was separated and related to the vaccine. There were no abnorstored at -70"C until analyzed.
malities in blood chemistry, hematology profiles, of antigen. The data obtained using NSIsV20 suggest the possibility of an immunosuppressive or urinalysis attributable to vaccine administra-epitope in the repeating (GDRA D/A GQPA) tion.
region of the P. vivax CS protein. The implication Six of the 9 volunteers who received either the of less than optimal immune responses reflected 100 or 1,000 jtg dose of PVSV-I developed an-in these data, combined with the recently retibodies to the vivax repeat epitopes as measured ported discovery of P. vivax isolates from Thaiby ELISA (Fig. 1) . Four of the individuals re-land which produce sporozoites that possess a ceiving the 100 jg dose had an initial response CS protein with significant differences in the reafter the first dose of vaccine, but failed to dem-peat region, 6 
